Risk stratification of patients with TP53-mutated myeloproliferative neoplasms
Authors:
- Benjamin RollesBRBenjamin Rolles
- Cilomar Martins de Oliveira FilhoCFCilomar Martins de Oliveira Filho
- Jan Philipp BewersdorfJBJan Philipp Bewersdorf
- Matthew SchwedeMSMatthew Schwede
- James EnglandJEJames England
- Marlise R. LuskinMLMarlise R. Luskin
- Daniel J. DeAngeloDDDaniel J. DeAngelo
- Shai ShimonySSShai Shimony
- 24 February 2026
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 40 (4) , 773-782
Abstract
While TP53 mutations in myeloproliferative neoplasms (MPN) are associated with an increased risk of leukemic transformation, not all patients carrying a TP53 mutation progress. To better risk-stratify MPN patients with TP53 mutations, we analyzed data from 1540 patients treated at four specialized cancer centers. Among them, 1429 had wildtype TP53 and 111 had mutations in the TP53 gene. At first MPN diagnosis, 32% had polycythemia vera, 39% had essential thrombocythemia, and 25% had primary myelofibrosis. Among all MPN patients with TP53 mutations, presence of fibrosis in the bone marrow (hazard ratio (HR): 3.84, 95% CI: 1.98–7.43), multi-hit TP53 mutation status (HR: 2.74, 95% confidence interval (CI): 1.52–4.97), and higher PHANTM score (HR: 1.87, 95% CI: 1.02–3.42) were associated with worse OS in a multivariable analysis. Based on these variables, we developed a risk model to identify TP53-mutated MPN patients who are at high risk for inferior OS. Median OS from time of TP53 detection was 0.5 years in high-risk patients, compared to 2.3 years for patients with intermediate risk and 6.3 years for patients with low risk. This scoring system may help refine risk stratification for chronic phase MPN patients harboring TP53 aberrations.Keywords
Funding Information
- Deutsche Krebshilfe (Mildred-Scheel scholarship No.70114570)
- Honoraria from GSK and Novartis
- National Institutes of Health (R01HL131835, R01 HL167139)
- U.S. Department of War (W81XWH2110909)
- Starr Foundation (I15-0026)
This publication has 33 references indexed in Scilit:
- Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohortBlood Cancer Journal, 2025
- TP53 Mutations in Myeloproliferative Neoplasms: Context‐Dependent Evaluation of Prognostic RelevanceAmerican Journal of Hematology, 2025
- Targeting tumor suppressor p53 for organ fibrosis therapyCell Death & Disease, 2024
- The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation‐enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosisAmerican Journal of Hematology, 2023
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic NeoplasmsLeukemia, 2022
- Decoding Bone Marrow Fibrosis in Myelodysplastic SyndromesClinical Lymphoma Myeloma and Leukemia, 2020
- GIPSS: genetically inspired prognostic scoring system for primary myelofibrosisLeukemia, 2018
- Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational statusLeukemia, 2017
- Mutations and prognosis in primary myelofibrosisLeukemia, 2013
- TP53 mutations and polymorphisms in primary myelofibrosisAmerican Journal of Hematology, 2011